# Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury

Source: https://onco.cc/trials/nct04485286/  
OnCo record `nct04485286` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in pancreatic cancer, run by Massachusetts General Hospital, now recruiting.

## Summary

Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury is a phase 2, interventional study registered as NCT04485286 by Massachusetts General Hospital, with a registry enrolment figure of 72 participants, started 2020-07-19 and due to reach its primary completion in 2027-05. Interventions recorded: [68Ga]CBP8. Conditions listed: Lung Cancer; Radiation Fibrosis; Radiation Induced Lung Injury; Pancreas Cancer. Primary outcome: Ability of [68Ga]CBP8 to detect collagen deposition in areas of radiation injury.. Pancreatic eligibility wording from the registry: "Inclusion Criteria for pancreatic cancer subjects:". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT04485286
- Phase: 2
- Setting: Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
- Sponsor: Massachusetts General Hospital
- Enrolled: 72

## Sources

- ClinicalTrials.gov NCT04485286: https://clinicaltrials.gov/study/NCT04485286

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct04485286.json